Valsartan capsule and preparation method thereof

Abstract

The invention relates to a valsartan capsule and a preparation method thereof. The valsartan capsule comprises an active component valsartan and hydroxypropylcellulose serving as a disintegrating agent and an adhesive. The preparation method of the valsartan capsule comprises the following steps that 1), valsartan is sieved by a 200-mesh sieve; a filling agent and hydroxypropylcellulose are sieved by an 80-mesh sieve, and mixed uniformly; 2), an alcohol solution with the concentration of 5-60% is prepared, and accounts for 45-55% of the gross weight of valsartan, hydroxypropylcellulose, the filling agent, a cosolvent and a lubricant, and the cosolvent is dissolved by a half of the alcohol solution; 3), valsartan premix powder is placed in a wet method granulator, the alcohol solution of the cosolvent is added, and the left alcohol solution and purified water are added according to a granulation situation of a material, and stirred to form wet particles sieved by a 14-mesh sieve; 4), the wet particles are dried and granulated; and 5), the particles are uniformly mixed with the lubricant sieved by the 80-mesh sieve and filled to form the valsartan capsule. The valsartan capsule can be disintegrated and dissolved out quickly, and is simple in technology and stable in quality.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a medicinal preparation and a preparation method thereof, in particular to a valsartan capsule and a preparation method thereof. Background technique [0002] Valsartan is a non-peptide angiotensin II receptor antagonist (ARB). In addition to treating hypertension, it can also be used to treat heart failure, acute myocardial infarction, prevent liver and kidney fibrosis, and protect blood vessels. , reduce the occurrence of diabetes and its complications, treat polycythemia after kidney transplantation and reduce the incidence of sexual dysfunction in male hypertensive patients. After being successfully developed by Swiss Novartis, it was first launched in Germany, and in the United States in 1997 under the product name "Diovan". After valsartan went on the market, Novartis developed a valsartan compound preparation. In October 1997, after the successful development of the valsa...

AI Technical Summary

Problems solved by technology

In the prescription, a large dose of povidone material is used. In the embodiment, the usage amount of povidone material is 6.8%-12.8%. Large, which will cause the product to grow rapidly during long-term storage, resulting in slower dissolution

Images